Estrogen receptors, hormonal imbalance, gynecomastia, hyperestrogenemia, and male breast cancer: a literature review

Male breast cancer (MBC) is a rare, malignant tumor. It occurs in men where it accounts for less than 1% of all breast cancers. This is linked with the hormonal imbalance of estrogen and androgen levels. The objective of this review is to provide the details about pathophysiology of gynecomastia (GM) caused by estrogen hormone imbalance along with the explanation of hyperestrogenemia caused by excessive estrogen, the treatment, the adjuvant, and preventive management of MBC currently used by clinical research. Treatment, prevention, and management strategies for MBC follow the similar protocols as for female breast cancer, but today’s treatment strategies include hormone-manipulating chemotherapy and biologics. The use of gene metabolites or active isomers, hormonal therapy and resection are also illustrated in clinical cases. Regarding the treatment and prevention of MBC, it is expected that the treatment strategies will shift to personalized medicine in the future, as it is difficult to identify mutant genes and perform effective genetic screening. Nevertheless, through our narrative review, this article discusses the differences between male and female breast cancer, the relationship between male hormones and breast cancer, and potential future treatment strategies.

Male breast cancer; Estrogen; Gynecomastia; Hyperestrogenemia

[1] Mansoor NS, Arifin F, Kornain NKM, Razalli MM. A rare invasive male breast cancer of nonspecific type presenting at a primary care clinic: importance of early diagnosis and management. Journal of Family and Community Medicine. 2023; 30: 65–67.

[2] Abdelwahab Yousef AJ. Male breast cancer: epidemiology and risk factors. Seminars in Oncology. 2017; 44: 267–272.

[3] Fentiman IS. Risk factors for male breast cancer. American Journal of Translational Research. 2023; 15: 6918–6925.

[4] Daniels J, Aduse-Poku AY, Gawu P. Overview of male breast cancer. World Journal of Advanced Research and Reviews. 2023; 17: 010–022.

[5] Mukherjee AG, Gopalakrishnan AV, Jayaraj R, Renu K, Dey A, Vellingiri B, et al. The incidence of male breast cancer: from fiction to reality—correspondence. International Journal of Surgery. 2023; 109: 2855–2858.

[6] Dunn N, Nguyen PD, Yuen SW, Lin E. Synchronous bilateral male breast cancer: a case report and review of literature. Journal of Case Reports and Images in Surgery. 2023; 9: 32–39.

[7] Niederberger P, Bucher S, Aebi S. Male breast cancer: what is different? Praxis. 2016; 105: 147–151.

[8] Yang Q, Kennicott K, Zhu R, Kim J, Wakefield H, Studener K, et al. Sex hormone influence on female-biased autoimmune diseases hints at puberty as an important factor in pathogenesis. Frontiers in Pediatrics. 2023; 11: 1051624.

[9] Hargrove-Wiley E, Fingleton B. Sex hormones in breast cancer immunity. Cancer Research. 2023; 83: 12–19.

[10] Sciarra F, Campolo F, Franceschini E, Carlomagno F, Venneri MA. Gender-specific impact of sex hormones on the immune system. International Journal of Molecular Sciences. 2023; 24: 6302.

[11] Fouhi ME, Mesfioui A, Benider A. Male breast cancer: a report of 25 cases. The Pan African Medical Journal. 2020; 37: 343.

[12] Shinde SD, Satpute DP, Behera SK, Kumar D. Computational biology of BRCA2 in male breast cancer, through prediction of probable nsSNPs, and hit identification. ACS Omega. 2022; 7: 30447–30461.

[13] Bradley JA, Gracie J, Mailhot Vega RB, Brooks ED, Burchianti T, Oladeru OT, et al. Proton therapy in the treatment of men with breast cancer. International Journal of Particle Therapy. 2023; 10: 94–104.

[14] Khan MZI, Uzair M, Nazli A, Chen J. An overview on Estrogen receptors signaling and its ligands in breast cancer. European Journal of Medicinal Chemistry. 2022; 241: 114658.

[15] Yu FL. 17Beta-estradiol epoxidation as the molecular basis for breast cancer initiation and prevention. Asia Pacific Journal of Clinical Nutrition. 2002; 7: S460–S466.

[16] Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen receptor function: impact on the human endometrium. Frontiers in Endocrinology. 2022; 13: 827724.

[17] Yoh K, Ikeda K, Horie K, Inoue S. Roles of estrogen, estrogen receptors, and estrogen-related receptors in skeletal muscle: regulation of mitochondrial function. International Journal of Molecular Sciences. 2023; 24: 1853.

[18] De Jesus AN, Henry BA. The role of oestrogen in determining sexual dimorphism in energy balance. The Journal of Physiology. 2023; 601: 435–449.

[19] Hess RA, Cooke PS. Estrogen in the male: a historical perspective. Biology of Reproduction. 2018; 99: 27–44.

[20] Hess RA, Sharpe RM, Hinton BT. Estrogens and development of the rete testis, efferent ductules, epididymis and vas deferens. Differentiation. 2021; 118: 41–71.

[21] Xin Y, Wang F, Ren D, Zhao F, Zhao J. Male breast cancer: three case reports and a literature review. Anti-Cancer Agents in Medicinal Chemistry. 2023; 23: 2161–2169.

[22] Jia M, Dahlman-Wright K, Gustafsson J. Estrogen receptor alpha and beta in health and disease. Best Practice & Research Clinical Endocrinology & Metabolism. 2015; 29: 557–568.

[23] Vermeulen MA, van Deurzen CHM, van Leeuwen-Stok AE, van Diest PJ. Elastosis in ERα-positive male breast cancer. Virchows Archiv. 2021; 478: 257–263.

[24] Plechner AJ. Cortisol abnormality as a cause of elevated estrogen and immune destabilization: insights for human medicine from a veterinary perspective. Medical Hypotheses. 2004; 62: 575–581.

[25] Gargiulo Isacco C, Ballini A, Paduanelli G, Inchingolo AD, Nguyen KCD, Inchingolo AM, et al. Bone decay and beyond: how can we approach it better. Journal of Biological Regulators and Homeostatic Agents. 2019; 33: 143–154.

[26] Li C, Li X. Case series analysis of male breast cancer. Indian Journal of Surgery. 2023; 85: 764–770.

[27] Severson TM, Zwart W. A review of estrogen receptor/androgen receptor genomics in male breast cancer. Endocrine-Related Cancer. 2017; 24: R27–R34.

[28] Sansone A, Romanelli F, Sansone M, Lenzi A, Di Luigi L. Gynecomastia and hormones. Endocrine. 2017; 55: 37–44.

[29] Fentiman IS. Risk factors for male breast cancer. American Journal of Translational Research. 2023; 15: 6918–6925.

[30] Ayyavoo A. Gynecomastia. Indian Journal of Pediatrics. 2023; 90: 1013–1017.

[31] Raheem AA, Zaghloul AS, Sadek AMG, Rayes B, Abdel-Raheem TM. The impact and management of gynaecomastia in klinefelter syndrome. Frontiers in Reproductive Health. 2021; 3: 629673.

[32] Barros AC, Sampaio Mde C . Gynecomastia: physiopathology, evaluation and treatment. São Paulo Medical Journal. 2012; 130: 187–197.

[33] Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1993; 13: 37–45.

[34] Cuhaci, Neslihan, Polat, Sefika Burcak, Evranos, Berna, et al. Clinical evaluation and management. Indian Journal of Endocrinology and Metabolism. 2014; 18: 150–158.

[35] Guss CE, Divasta AD. Adolescent gynecomastia. Pediatric Endocrinology Reviews. 2017; 14: 371–377.

[36] Soliman AT, De Sanctis V, Yassin M. Management of adolescent gynecomastia: an update. Acta Biomedica. 2017; 88: 204–213.

[37] Karamchandani MM, De La Cruz Ku G, Sokol BL, Chatterjee A, Homsy C. Management of gynecomastia and male benign diseases. Surgical Clinics of North America. 2022; 102: 989–1005.

[38] Narula HS, Carlson HE. Gynaecomastia—pathophysiology, diagnosis and treatment. Nature Reviews Endocrinology. 2014; 10: 684–698.

[39] Pinelli M, De Maria F, Ceccarelli P, Pedrieri B, Bianchini MA, Iughetti L, et al. Gynecomastia: an uncommon, destabilizing condition of the male adolescent. our therapeutic choice. Acta Biomedica. 2023; 94: e2023055.

[40] Barros AC, Sampaio Mde C. Gynecomastia: physiopathology, evaluation and treatment. Sao Paulo Medical Journal. 2012; 130: 187–197.

[41] Salvio G, Martino M, Giancola G, Arnaldi G, Balercia G. Hypothalamic-pituitary diseases and erectile dysfunction. Journal of Clinical Medicine. 2021; 10: 2551.

[42] Seminara G, Chiarello P, Iuliano R, Tinelli E, Sabatini U, Iuliano S, et al. Gynecomastia and leydigioma: an unexpected case report outcome. Endocrines. 2023; 4: 656–663.

[43] Han YK, Ting W, Ting P, Yv XB, Xi SR, Gang L. Case report on gynecomastia with ipsilateral recurrence of granulomatous lobular mastitis. Journal of International Medical Research. 2023; 51: 3000605231187815.

[44] Mohammadnia N, Simsek S, Stam F. Gynecomastia as a presenting symptom of Graves’ disease in a 49-year-old man. Endocrinology, Diabetes & Metabolism Case Reports. 2021; 2021: 20–0181.

[45] Yin L, Agyekum EA, Zhang Q, Wu T, Qian X. Gynecomastia with rare granulomatous lobular mastitis: a case report and literature review. Journal of International Medical Research. 2022; 50: 3000605221075815.

[46] Jaruratanasirikul S, Janejindamai S. Idiopathic hyperprolactinemia in a 15-year-old boy: a case report and literature review. Journal of the Medical Association of Thailand. 1995; 78: 388–392.

[47] Ohyama K, Tanaka H, Shindo J, Shibayama M, Iwata M, Hori Y. Association of gynecomastia with antidiabetic medications in older adults: data mining from different national pharmacovigilance databases. International Journal of Clinical Pharmacology and Therapeutics. 2022; 60: 24–31.

[48] Senkoro E, Varadarajan M, Candela C, Gebreselassie A, Antoniadi C, Boffito M. Anastrozole as a therapeutic option for gynecomastia in a person receiving antiretroviral therapy: case report. British Journal of Clinical Pharmacology. 2024; 90: 350–353.

[49] Fricke A, Lehner GM, Stark GB, Penna V. Gynecomastia: histological appearance in different age groups. Journal of Plastic Surgery and Hand Surgery. 2018; 52: 166–171.

[50] Jabori SK, Hullfish H, Samaha Y, Becker H, Thaller SR. Unraveling the enigma: a rare case of recurrent idiopathic gynecomastia in an adolescent. Journal of Craniofacial Surgery. 2024; 35: 208–210.

[51] Leinung S, Horn LC, Backe J. Male breast cancer: history, epidemiology, genetic and histopathology. Zentralblatt fur Chirurgie. 2007; 132: 379–385.

[52] Lee J, Shin DM, Oh SJ, Park J, Lee D. A case of Cowden syndrome presenting with diverse cutaneous manifestations. Annals of Dermatology. 2023; 35: 146–150.

[53] Tariq KB, Al-Saffar F, Ibrahim S, Pham D, Farhangi A, Rana F, et al. Male breast cancer and hyperestrogenemia: a thirteen-year review. World Journal of Oncology. 2014; 5: 55–61.

[54] Yevhen Hotko. The significance of hormone receptors in male breast cancer. To be published in Research Square. 2020. [Preprint].

[55] Karamanakos P, Mitsiades CS, Lembessis P, Kontos M, Trafalis D, Koutsilieris M, et al. Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy. Anticancer Research. 2004; 24: 1077–1082.

[56] Bouraïma H, Lireux B, Mittre H, Benhaim A, Herrou M, Mahoudeau J, et al. Major hyperestrogenism in a feminizing adrenocortical adenoma despite a moderate overexpression of the aromatase enzyme. European Journal of Endocrinology. 2003; 148: 457–461.

[57] Zavadenko NN. Study of the hypophyseal-gonadal system in patients with hereditary muscular dystrophy. Zhurnal Nevropatologii i Psikhiatrii Imeni SS Korsakova. 1990; 90: 25–28. (In Russian)

[58] Zumoff B, Strain GW. A perspective on the hormonal abnormalities of obesity: are they cause or effect? Obesity Research. 1994; 2: 56–67.

[59] Cohen PG. Obesity in men: the hypogonadal–estrogen receptor relationship and its effect on glucose homeostasis. Medical Hypotheses. 2008; 70: 358–360.

[60] Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Medical Hypotheses. 2001; 56: 702–708.

[61] Jesmin S, Mowa CN, Sakuma I, Matsuda N, Togashi H, Yoshioka M, et al. Aromatase is abundantly expressed by neonatal rat penis but downregulated in adulthood. Journal of Molecular Endocrinology. 2004; 33: 343–359.

[62] Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology. 2007; 53: 1–22.

[63] Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. European Journal of Nuclear Medicine and Molecular Imaging. 2004; 31: S149–S161.

[64] Ottini L, Capalbo C, Rizzolo P, Silvestri V, Bronte G, Rizzo S, et al. HER2-positive male breast cancer: an update. Breast Cancer. 2010; 2: 45–58.

[65] Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treatment Reviews. 2014; 40: 259–270.

[66] Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, et al. Targeted therapy in breast cancer. Molecular & Cellular Proteomics. 2004; 3: 379–398.

[67] Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, et al. Management of male breast cancer: ASCO guideline. Journal of Clinical Oncology. 2020; 38: 1849–1863.

[68] Gao Y, Heller SL, Moy L. Male breast cancer in the age of genetic testing: an opportunity for early detection, tailored therapy, and surveillance. RadioGraphics. 2018; 38: 1289–1311.

[69] Constantinou N, Marshall C, Marshall H. Discussion and optimization of the male breast cancer patient experience. Journal of Breast Imaging. 2023; 5: 339–345.

[70] Fentiman IS. Neoadjuvant treatment for male breast cancer. Translational Cancer Research. 2023; 12: 1669–1671.

[71] Dogan I, Khanmammadov N, Ozkurt S, Aydiner A, Saip P. Outcomes of the patients with metastatic male breast cancer. Journal of Cancer Research and Therapeutics. 2023; 8: 1–5.

[72] Jayaraman S, Reid JM, Hawse JR, Goetz MP. Endoxifen, an estrogen receptor targeted therapy: from bench to bedside. Endocrinology. 2021; 162: bqab191.

[73] Onami S, Ozaki M, Mortimer JE, Pal SK. Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas. 2010; 65: 308–314.

[74] Katayama K, Yamagishi J, Kashiwagi B. A case of male breast cancer for which mTOR inhibitor was effective with advanced renal cancer. Gan To Kagaku Ryoho. 2013; 40: 365–369.

[75] Ambareen S, Rani K, Kerketta ZH, Murari K. Recent scenario of male breast cancer in a tertiary care centre. Asian Pacific Journal of Cancer Care. 2024; 9: 3–7.

[76] Wong WG, Perez Holguin RA, Kanwar R, Dodge D, Shen C. Management of male patients with occult breast cancer: analysis of the national cancer database. Journal of Surgical Research. 2024; 293: 685–692.

[77] Wang S, He P, Liu Q, Mao J, Shen S. Impact of evidence-based nursing on postoperative psychological state, quality of life, and function of affected limbs in breast cancer patients: an observational study. Medicine. 2024; 103: e36788.

[78] Vizza R, Capomolla EM, Tosetto L, Corrado G, Bruno V, Chiofalo B, et al. Sexual dysfunctions in breast cancer patients: evidence in context. Sexual Medicine Reviews. 2023; 11: 179–195.

[79] Valentini V, Silverstri V, Bucalo A, Conti G, Karimi M, Francesco LD, et al. Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology. Frontiers in Oncology. 2023; 12: 1092201.